E Fund Management Co. Ltd. Sells 15,243 Shares of ADMA Biologics, Inc. (NASDAQ:ADMA)

E Fund Management Co. Ltd. reduced its holdings in shares of ADMA Biologics, Inc. (NASDAQ:ADMA) by 47.3% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 16,998 shares of the biotechnology company’s stock after selling 15,243 shares during the period. E Fund Management Co. Ltd.’s holdings in ADMA Biologics were worth $190,000 at the end of the most recent reporting period.

Several other large investors have also recently made changes to their positions in the business. Mesirow Institutional Investment Management Inc. purchased a new stake in shares of ADMA Biologics in the 1st quarter valued at $17,221,000. Castleark Management LLC bought a new stake in ADMA Biologics in the first quarter worth $5,400,000. Hillsdale Investment Management Inc. boosted its position in ADMA Biologics by 41,893.3% during the first quarter. Hillsdale Investment Management Inc. now owns 629,900 shares of the biotechnology company’s stock valued at $4,157,000 after buying an additional 628,400 shares during the period. Renaissance Technologies LLC grew its stake in shares of ADMA Biologics by 28.7% during the second quarter. Renaissance Technologies LLC now owns 2,582,135 shares of the biotechnology company’s stock valued at $28,868,000 after buying an additional 575,100 shares during the last quarter. Finally, Russell Investments Group Ltd. grew its stake in shares of ADMA Biologics by 90.7% during the first quarter. Russell Investments Group Ltd. now owns 1,169,207 shares of the biotechnology company’s stock valued at $7,717,000 after buying an additional 556,175 shares during the last quarter. 75.68% of the stock is owned by hedge funds and other institutional investors.

ADMA Biologics Stock Up 2.2 %

Shares of NASDAQ:ADMA opened at $19.74 on Friday. The stock’s 50-day moving average is $15.63 and its 200 day moving average is $10.83. The company has a market cap of $4.58 billion, a PE ratio of -987.00 and a beta of 0.61. The company has a debt-to-equity ratio of 0.74, a current ratio of 6.87 and a quick ratio of 2.80. ADMA Biologics, Inc. has a 1 year low of $3.06 and a 1 year high of $19.92.

ADMA Biologics (NASDAQ:ADMA) last posted its earnings results on Thursday, August 8th. The biotechnology company reported $0.13 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.08 by $0.05. ADMA Biologics had a return on equity of 38.79% and a net margin of 10.53%. The firm had revenue of $107.20 million for the quarter, compared to analysts’ expectations of $86.44 million. During the same period in the previous year, the firm earned ($0.02) earnings per share. The business’s revenue was up 78.4% compared to the same quarter last year. Sell-side analysts anticipate that ADMA Biologics, Inc. will post 0.49 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently weighed in on the company. HC Wainwright boosted their target price on ADMA Biologics from $10.00 to $18.00 and gave the company a “buy” rating in a research note on Monday, August 12th. Mizuho increased their price objective on ADMA Biologics from $12.00 to $14.00 and gave the company a “buy” rating in a research note on Thursday, June 20th. Finally, Cantor Fitzgerald lifted their target price on shares of ADMA Biologics from $15.00 to $20.00 and gave the stock an “overweight” rating in a research note on Friday, August 9th. One research analyst has rated the stock with a hold rating, three have given a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, ADMA Biologics presently has a consensus rating of “Buy” and an average price target of $15.50.

Insider Buying and Selling at ADMA Biologics

In other news, CEO Adam S. Grossman sold 236,889 shares of the firm’s stock in a transaction dated Monday, August 26th. The shares were sold at an average price of $17.69, for a total value of $4,190,566.41. Following the completion of the sale, the chief executive officer now directly owns 2,059,726 shares of the company’s stock, valued at approximately $36,436,552.94. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. In related news, Director Lawrence P. Guiheen sold 9,000 shares of the company’s stock in a transaction on Monday, September 9th. The stock was sold at an average price of $18.47, for a total value of $166,230.00. Following the sale, the director now directly owns 153,941 shares of the company’s stock, valued at $2,843,290.27. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, CEO Adam S. Grossman sold 236,889 shares of the firm’s stock in a transaction on Monday, August 26th. The shares were sold at an average price of $17.69, for a total value of $4,190,566.41. Following the transaction, the chief executive officer now directly owns 2,059,726 shares of the company’s stock, valued at approximately $36,436,552.94. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 466,900 shares of company stock valued at $8,224,121. 3.70% of the stock is currently owned by company insiders.

About ADMA Biologics

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.